BioWorld Asia

July 2, 2008

EU Drug Development Slowdown Due to Biotech Complexity?

BRUSSELS, Belgium - There is a slowdown in the volume of useful new drugs on the European market, and biotech is in part to blame, according to the leading European pharmaceutical industry association. (BioWorld International) Read More

Alizyme, Norgine Team Up in $67M Marketing Deal

Blood Vessel Growth Blocker Could Be Used to Starve Tumors

Short of Money and Time, Ardana Biosciences Dies

Patent Infringement Claim Filed Against Oxford Biomedica

Oxford Profs Found Celleron to Scope Tumor Sensitivity

Immutep Reports Positive Results from LAG-3 Immunotherapy

Ascenion Adds Protectimmun to its Investment Portfolio

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

Alicorn synthesizes new AAK1 inhibitors

BioWorld Science

Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...

Illustration of glucose in the blood stream

CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research

BioWorld Science

Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...

Saniona reports preclinical data for SAN-2668

BioWorld Science

Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which is a GABA-A receptor positive...

CC-3 antibody shows antitumoral activity in penile cancer

BioWorld Science

Advanced penile cancer (PeCa) is a rare cancer affecting the genitourinary tract with a 5-year survival rate of about 10% when metastatic. First-line therapies...